Advaxis’ senior management team hosted an Analyst and Investor Day featuring an overview of its proprietary technology platform, clinical and corporate milestones for 2016 and evidence-based scientific presentations from principal investigators leading the company’s Lm Technology™ immunotherapy cross-tumor preclinical and clinical study programs.
The full webcast and presentation slides from the 2016 Analyst and Investor Day can be accessed via this link.
Precise goals of the event were two-fold:
- To offer an open opportunity to interact with physicians actively working with the Advaxis immunotherapy technology; and
- To provide a transparent understanding of company scientific and clinical goals in 2016 and beyond.